Related Experiment Videos
Tyrosine kinase inhibitors in preclinical development
1Chaim Sheba Medical Center, Tel Hashomer, Israel.
Abstract:
Due to the limited efficacy of cytotoxic chemotherapy in the treatment of advanced malignancy and its excessive toxicity precluding its use in chemoprevention, new therapeutic and preventive strategies have been sought. One of the most interesting of these new approaches is the manipulation of signal transduction pathways. Among the approaches being considered to eventuate such a strategy is the inhibition of autophosphorylation, a critical first step in the signal transduction pathways of many cell surface receptor tyrosine kinases, as well as of non-receptor tyrosine kinases. This article is intended to review those tyrosine kinase inhibitors that are currently in preclinical development, for which there are data to support consideration for their use in chemoprevention or cancer treatment. We will focus upon those agents that have received attention in the past several years.
Insights
New tyrosine kinase inhibitors are being developed to overcome chemotherapy limitations. These agents target critical signaling pathways for cancer treatment and prevention, offering a promising alternative.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cytotoxic chemotherapy has limited efficacy and high toxicity for advanced cancers and chemoprevention.
- Signal transduction pathway manipulation is a promising new therapeutic and preventive strategy.
- Inhibition of autophosphorylation is a key step in targeting tyrosine kinases.
Purpose of the Study:
- To review tyrosine kinase inhibitors in preclinical development.
- To assess their potential for cancer treatment and chemoprevention.
- To focus on agents receiving recent attention.
Main Methods:
- Literature review of preclinical tyrosine kinase inhibitors.
- Analysis of data supporting their use in cancer therapy and prevention.
- Focus on agents developed in recent years.
Main Results:
- Several tyrosine kinase inhibitors are in preclinical development.
- Data suggest potential for both cancer treatment and chemoprevention.
- Recent research highlights specific agents of interest.
Conclusions:
- Tyrosine kinase inhibitors represent a promising area for novel cancer therapies.
- Targeting signal transduction pathways offers an alternative to traditional chemotherapy.
- Further preclinical development is warranted for these agents.